Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6094)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 15, 2024 (publication date) through Dec 16, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Zhou J, Zhang MY, Gao AA, Zhu C, He T, Herman JG, Guo MZ. Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor. World J Gastrointest Oncol 2024; 16(5): 2060-2073 [PMID: 38764821 DOI: 10.4251/wjgo.v16.i5.2060] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Zhou J, Zhang MY, Gao AA, Zhu C, He T, Herman JG, Guo MZ. Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor. World J Gastrointest Oncol 2024; 16(5): 2060-2073 [PMID: 38764821 DOI: 10.4251/wjgo.v16.i5.2060] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v16/i5/2060.htm |
| Number | Citing Articles |
| 1 |
Eleonora Allavena, Michela Croce, Bruna Dalmasso, Cecilia Profumo, Valentina Rigo, Virginia Andreotti, Irene Vanni, Benedetta Pellegrino, Antonino Musolino, Nicoletta Campanini, William Bruno, Luca Mastracci, Gabriele Zoppoli, Enrica Teresa Tanda, Francesco Spagnolo, Paola Ghiorzo, Lorenza Pastorino. Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma. International Journal of Molecular Sciences 2025; 26(15): 7420 doi: 10.3390/ijms26157420
|
| 2 |
Kunzhong Zhou, Yuewen Li, Weifang Wang, Yilin Chen, Bingyan Qian, Yiteng Liang, Hongmei Li, Ruiting Xu, Li Zhuang. SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1582738
|
| 3 |
Hao Xiao, Zeping Han, Yingkai Tang, Xukang Gao, Min Xu, Shuangjian Qiu, Ning Ren, Yong Yi, Chenhao Zhou. SLFN11, far from being limited to responding to cancer DNA damage. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01776-y
|
| 4 |
Yue Feng, Yingze Li, Zhenhao Zhang, Yuxuan Dai, Xingchun Gou, Kejing Lao, Running Zhang. From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity. Cancer Chemotherapy and Pharmacology 2025; 95(1) doi: 10.1007/s00280-025-04781-w
|
| 5 |
Shuang Xu, Kang Liu, Dan Zhang, Xiang Wang, Ying Luo, Nengming Lin. Schlafen 11 as a predictive biomarker and therapeutic target in cancer: From mechanisms to clinical application. Drug Discovery Today 2025; : 104579 doi: 10.1016/j.drudis.2025.104579
|
| 6 |
Maria Farina-Morillas, Laia Ollé-Monràs, Silvana CE Maas, Isabel de Rojas-P, Miguel F. Segura, Jose A. Seoane. Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches. Epigenomics 2025; 17(15): 1069 doi: 10.1080/17501911.2025.2548756
|
| 7 |
Jae Hyeong Kim, Yuna Youn, Jin-Hyeok Hwang. <i>SLFN11</i> Deficiency-Induced Gemcitabine Resistance Is Overcome by Agents Targeting the DNA Damage Response in Pancreatic Cancer Cells. BIOCELL 2025; 49(4): 681 doi: 10.32604/biocell.2025.062144
|